| Date | Title | Description |
| 03.02.2026 | UK Government Embraces Activist Investment, Fuels "Picking Winners" Debate | The UK government champions an activist investment strategy. Business Secretary Peter Kyle explicitly backs "picking winners." He defends state intervention through entities like the British Business Bank. Kyle views calculated ri... |
| 30.01.2026 | Epidarex Capital Secures $145+ Million First Close For Fund IV To Invest In Life Science Startups | Epidarex Capital announced it has reached a first close of Epidarex Capital IV, LP, with more than $145 million in commitments, as the transatlantic life sciences venture firm looks to expand its company creation and early-stage investing a... |
| 24.01.2026 | Investor hits out at Peter Kyle for ‘picking winners’ | Business secretary Peter Kyle has come under fire over his admission the government would be “picking winners” across the UK economy.
The former Gail’s and Pizza Express investor Luke Johnson hit out at Kyle’s “arrogance and equal measure” ... |
| 06.10.2025 | Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment | Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the establishment of the second gen... |
| 10.09.2024 | Epsilogen Secures £12.5 Million to Propel Cancer Treatment Innovations | Epsilogen, a pioneering force in the realm of immunoglobulin E (IgE) antibodies, has successfully raised £12.5 million in a Series B funding round. This brings the total Series B financing to an impressive £43.25 million. The funds will be ... |
| 09.09.2024 | Epsilogen: Immunoglobulin Development Company Raises £12.5 Million (Series B) | Epsilogen – a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer – announced today the completion of a £12.5 million Series B expansion financing, bringing the Series B total to £43.25 million. The funding will a... |
| 21.10.2021 | VCs back Leucid to trial CAR-T twist in ovarian cancer patients | John Maher, Ph.D., has secured funding to put his ideas about CAR-Ts to the test. As chief scientific officer of Leucid Bio, Maher has pushed the idea that the configuration of co-stimulatory modules is the secret to success in CAR-T—and no... |
| 06.10.2021 | Starting a health technology company in Baltimore? Here are 43 resources to know | The digital health sector was growing rapidly. Then the pandemic came.
In this case, it was a story of growth.
Following distancing requirements and loosening regulations, telemedicine became the name of the game for many healthcare systems... |
| 23.06.2021 | RapidPulse Launches with $15M for Ischemic Stroke Therapy | – RapidPulse, Inc., a Miami-based medical device company developing a novel aspiration system to treat ischemic stroke, today announced it has raised $15M in Series A funding led by Santé Ventures who was joined by Epidarex Capital, Hattera... |
| 02.06.2021 | Baltimore’s startup community has a model. Now it needs to scale | Startups can’t stay in the early stage forever.
While a young company can benefit from the early momentum of pitch wins and resources found in a community, it eventually must figure out its business model, and ultimately scale.
Hearing lead... |
| 19.01.2021 | Slate Bio Closes $1.75 Million Seed Financing | Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology’s GAP Bi... |
| 07.01.2021 | News briefing: Pfizer kickstarts PhIII trial for DMD gene therapy, outracing Sarepta; Teva's reformulated schizophrenia shot touts win in late-stage study | In the race to bring the first gene therapy for Duchenne muscular dystrophy into a Phase III trial, Pfizer has come out on top over competitor Sarepta, dosing its first patient in the CIFFREO study, the pharma giant said Th... |
| 16.10.2020 | Need startup funding? Here are 75+ venture capital firms in the Baltimore-DC region | If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the Baltimore-D.C. region don’t need to go so far to find a firm that c... |
| 13.10.2020 | Need startup funding? Here are 75+ venture capital firms in the DMV region | If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the DMV region don’t need to go so far to find a firm that could propel... |
| 22.06.2020 | Epidarex Capital Closes New £102 Million UK Venture Fund | Epidarex Capital, a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emergin... |
| 22.06.2020 | Epidarex Capital Raises £102M UK Venture Fund | Epidarex Capital, a transatlantic life science venture firm, closed Epidarex Capital III UK LP, at £102.1m.
The fund will build new life science companies based on research and innovation from emerging hubs across the UK, including spinouts... |
| 14.11.2019 | Lunac Therapeutics Raises £2.65M in Series A Funding | Lunac Therapeutics, a Leeds, England, UK-based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, raised £2.65M in funding in the first close of a Series A financing r... |
| 29.08.2019 | LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases | LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on ... |
| 29.08.2019 | LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases | LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on ... |
| 12.04.2018 | Novartis Venture Co-led $41M Series B for Enterprise Therapeutics | Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million U... |
| 12.04.2018 | Epidarex-backed Enterprise Therapeutics Raises £29M ($41M) Funding | Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million U... |
| 14.11.2017 | Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes IPO | Epidarex Capital, an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering of its portfolio company Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the ... |
| 06.11.2015 | Caldan Therapeutics Raises £4.45M in Series A Funding | Caldan Therapeutics Ltd, a Glasgow, UK-based diabetes startup, raised £4.45m in Series A funding.
The round was led by Epidarex Capital, an international early-stage life science venture capital fund, with participation from Scottish Enterp... |
| 20.05.2015 | Enterprise Therapeutics Secures £2.4M in Series A Financing | Enterprise Therapeutics, a Brighton, UK-based drug discovery company focused on new therapeutics for respiratory diseases, secured an additional £2.4m ($3.6m) in Series A financing.
The funds included £2m by new investor Imperial Innovation... |
| 16.02.2015 | Enterprise Therapeutics Secures £1.6M in Series A Financing | Enterprise Therapeutics, a Brighton, Sussex, UK-based drug discovery company focused on new therapeutics for respiratory diseases, secured £1.6m (approximately $2.4m) in Series A financing.
Epidarex Capital made the investment.
The company ... |
| 04.12.2014 | Sirakoss Secures $4.8M in Series A Financing | Sirakoss, an Edinburgh and Aberdeen, UK-based medical device company, secured $4.8m in Series A financing.
The round was led by Epidarex Capital, with participation from the Scottish Investment Bank and the Worshipful Company of Armourers &... |
| 30.05.2014 | Epidarex Capital Closes £47.5M Life Science and Health Tech Fund | Venture capital firm Epidarex Capital raised £47.5m (over $80m) for a UK-based early-stage life science and health tech fund.
Limited partners include King’s College London, Eli Lilly and Co., the European Investment Fund, Scottish Enterpri... |
| 26.02.2014 | Confluence Life Sciences Raises Capital |
ST. LOUIS, MO, Epidarex Capital has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory disease.
>> Cl... |
| 08.02.2014 | Edinburgh Molecular Imaging Closes £4m Series A Funding | Edinburgh Molecular Imaging, a Scottish (UK) developer of optical molecular imaging technology, closed a £4m Series A funding.
Backers included Epidarex Capital and the Scottish Investment Bank.
Co-founded by Professor Mark Bradley, Profess... |
